NCT04372641: Testing the Safety of CB-5339 in Patients With Cancer

NCT04372641
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with unstable untreated brain metastases that require therapy – see trial for details
https://ClinicalTrials.gov/show/NCT04372641

Comments are closed.

Up ↑